353 related articles for article (PubMed ID: 20859081)
1. Cutaneous myelofibrosis with JAK2 V617F mutation: metastasis, not merely extramedullary hematopoiesis!
Fraga GR; Caughron SK
Am J Dermatopathol; 2010 Oct; 32(7):727-30. PubMed ID: 20859081
[TBL] [Abstract][Full Text] [Related]
2. JAK2-positive cutaneous myelofibrosis presenting as sclerosing extramedullary hematopoietic tumors on the scalp: case presentation and review of the literature.
LeBlanc RE; Lester L; Kwong B; Rieger KE
J Cutan Pathol; 2015 Nov; 42(11):858-62. PubMed ID: 26153565
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
[TBL] [Abstract][Full Text] [Related]
4. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
5. [Idiopathic myelofibrosis with cutaneous extramedullary hematopoiesis].
Rodríguez Ramírez J; Redondo Martínez E; Bosch Benítez J; López Mirones E; Gómez Díaz J; Betancor León P
Med Clin (Barc); 1991 Jun; 97(1):24-6. PubMed ID: 1857143
[TBL] [Abstract][Full Text] [Related]
6. Extramedullary peritoneal hematopoiesis combined with tuberculosis in a patient with primary myelofibrosis.
Kim SJ; Lee Y; Kim SH; Kim H; Park KU; Bang SM; Lee JS
Med Oncol; 2009; 26(2):238-41. PubMed ID: 18850308
[TBL] [Abstract][Full Text] [Related]
7. Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
Kreft A; Springer E; Lipka DB; Kirkpatrick CJ
Acta Haematol; 2009; 122(1):36-8. PubMed ID: 19713696
[TBL] [Abstract][Full Text] [Related]
8. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous extramedullary hematopoiesis in a patient with idiopathic myelofibrosis.
Miyata T; Masuzawa M; Katsuoka K; Higashihara M
J Dermatol; 2008 Jul; 35(7):456-61. PubMed ID: 18705835
[TBL] [Abstract][Full Text] [Related]
10. [A case of cutaneous extramedullary hematopoiesis associated with idiopathic myelofibrosis].
Corella F; Barnadas MA; Bordes R; Curell R; Espinosa I; Vergara C; Alomar A
Actas Dermosifiliogr; 2008 May; 99(4):297-300. PubMed ID: 18394406
[TBL] [Abstract][Full Text] [Related]
11. [Idiopathic myelofibrosis with extramedullary hematopoiesis foci in the skin and testicles. Report of a case].
Ruberto E; Espinola R; Brusco J; Bacchiocchi M; Zoppi J; Paz R
Sangre (Barc); 1995 Apr; 40(2):157-60. PubMed ID: 7784946
[TBL] [Abstract][Full Text] [Related]
12. JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.
Catarsi P; Rosti V; Morreale G; Poletto V; Villani L; Bertorelli R; Pedrazzini M; Zorzetto M; Barosi G;
PLoS One; 2015; 10(1):e0116636. PubMed ID: 25617626
[TBL] [Abstract][Full Text] [Related]
13. The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
Kremer M; Horn T; Dechow T; Tzankov A; Quintanilla-Martínez L; Fend F
Leukemia; 2006 Jul; 20(7):1315-6. PubMed ID: 16617316
[No Abstract] [Full Text] [Related]
14. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
15. Autopsy case of primary myelofibrosis in which myeloid sarcoma was the initial manifestation of tumor progression.
Morita K; Nakamine H; Inoue R; Takano M; Takeda M; Enomoto Y; Kasai T; Nonomura A; Tanaka H; Amano I; Morii T; Kimura H
Pathol Int; 2012 Jun; 62(6):433-7. PubMed ID: 22612514
[TBL] [Abstract][Full Text] [Related]
16. Reply to Kremer M et al., the JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
Ohyashiki K; Ohyashiki JH
Leukemia; 2006 Jul; 20(7):1297-8. PubMed ID: 16617315
[No Abstract] [Full Text] [Related]
17. Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele.
Pieri L; Guglielmelli P; Bogani C; Bosi A; Vannucchi AM;
Leuk Res; 2008 Mar; 32(3):516-7. PubMed ID: 17706283
[No Abstract] [Full Text] [Related]
18. [Cutaneous extramedullary hematopoiesis in myelofibrosis].
Roupe G
Hautarzt; 1987 Apr; 38(4):230-1. PubMed ID: 3597090
[TBL] [Abstract][Full Text] [Related]
19. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Rosillo C; Camoriano JK
Am J Hematol; 2007 May; 82(5):400-2. PubMed ID: 17133423
[TBL] [Abstract][Full Text] [Related]
20. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
